ZYFLO TO THE RESCUE?
Host-directed therapy shows preclinical success in TB
By Anette Breindl
Thursday, July 3, 2014
As increasing bacterial drug resistance threatens to usher in a post-antibiotic era, one strategy being explored is so-called host-directed therapy trying to give the immune system of an infected person a leg up against what ails them.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.